33.02
price down icon4.48%   -1.55
pre-market  시장 영업 전:  33.08   0.06   +0.18%
loading
전일 마감가:
$34.57
열려 있는:
$33.85
하루 거래량:
2.81M
Relative Volume:
1.02
시가총액:
$6.28B
수익:
$217.77M
순이익/손실:
$-438.86M
주가수익비율:
-13.70
EPS:
-2.41
순현금흐름:
$-456.33M
1주 성능:
-10.13%
1개월 성능:
-5.39%
6개월 성능:
+33.15%
1년 성능:
+10.14%
1일 변동 폭
Value
$32.84
$34.50
1주일 범위
Value
$32.84
$37.06
52주 변동 폭
Value
$21.62
$39.47

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name
명칭
Bridgebio Pharma Inc
Name
전화
(650) 391-9740
Name
주소
3160 PORTER DR., PALO ALTO, CA
Name
직원
730
Name
트위터
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
BBIO's Discussions on Twitter

BBIO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
BBIO
Bridgebio Pharma Inc
33.02 6.28B 217.77M -438.86M -456.33M -2.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-10-16 개시 Scotiabank Sector Outperform
2024-10-03 개시 Oppenheimer Perform
2024-09-04 개시 Piper Sandler Overweight
2024-03-21 재개 Raymond James Outperform
2024-01-31 개시 BMO Capital Markets Market Perform
2023-12-08 개시 Wells Fargo Overweight
2023-11-07 개시 Citigroup Buy
2023-10-24 개시 Cantor Fitzgerald Overweight
2023-07-18 다운그레이드 Jefferies Buy → Hold
2023-04-19 개시 Evercore ISI Outperform
2023-02-06 개시 Cowen Outperform
2021-12-27 재확인 Mizuho Buy
2021-12-27 재확인 SVB Leerink Outperform
2021-09-10 업그레이드 BofA Securities Neutral → Buy
2021-05-21 개시 UBS Buy
2021-03-22 재확인 Goldman Buy
2021-02-22 재개 JP Morgan Overweight
2021-02-09 재개 Goldman Buy
2021-01-11 재확인 H.C. Wainwright Buy
2020-12-10 재확인 H.C. Wainwright Buy
2020-06-25 개시 BofA/Merrill Neutral
2020-05-19 개시 BTIG Research Buy
2020-04-13 개시 H.C. Wainwright Buy
2020-02-19 개시 Mizuho Buy
2019-07-26 개시 Raymond James Outperform
2019-07-22 개시 BMO Capital Markets Outperform
2019-07-22 개시 Goldman Buy
2019-07-22 개시 JP Morgan Overweight
2019-07-22 개시 Jefferies Buy
2019-07-22 개시 Piper Jaffray Overweight
2019-07-22 개시 SVB Leerink Outperform
모두보기

Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스

pulisher
Apr 01, 2025

Raymond James maintains $57 target on BridgeBio stock By Investing.com - Investing.com Canada

Apr 01, 2025
pulisher
Apr 01, 2025

Revolutionary Dual-State KRAS Inhibitor Enters Clinical Trials for Advanced Cancer Treatment - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

Acoramidis shows promise in ATTR-CM Phase 3 trial By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Redburn Atlantic Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - Nasdaq

Mar 31, 2025
pulisher
Mar 31, 2025

BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Acoramidis shows promise in ATTR-CM Phase 3 trial - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Breakthrough: New ATTR-CM Drug Shows Dramatic 59% Risk Reduction in Phase 3 Trial - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target - Marketscreener.com

Mar 31, 2025
pulisher
Mar 31, 2025

Redburn-Atlantic sets $50 target for BridgeBio stock with Buy rating - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Pictet Asset Management Holding SA Sells 995,585 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat

Mar 31, 2025
pulisher
Mar 29, 2025

Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey

Mar 29, 2025
pulisher
Mar 29, 2025

(BBIO) Technical Data - news.stocktradersdaily.com

Mar 29, 2025
pulisher
Mar 29, 2025

Genmab and BridgeBio Pharma announce Japan approval for their treatments - MSN

Mar 29, 2025
pulisher
Mar 27, 2025

BridgeBio Pharma CEO sells $2.76 million in stock By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 27, 2025

BridgeBio Pharma CEO sells $2.76 million in stock - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Japan approves new ATTR-CM treatment Beyonttra By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

BridgeBio’s Beyonttra approved in Japan - The Pharma Letter

Mar 27, 2025
pulisher
Mar 27, 2025

BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

BridgeBio Announces Approval Of Beyonttra In Japan; To Receive $30 Mln Milestone Payment - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

Beyonttra(TM) (Acoramidis), The First Near-Complete TTR Stabilizer (>=90%), Approved in Japan To Treat ATTR-CM - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Japan approves new ATTR-CM treatment Beyonttra - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Game-Changing Heart Disease Drug Beyonttra Achieves 42% Mortality Reduction in Japan - Stock Titan

Mar 27, 2025
pulisher
Mar 24, 2025

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions - The Manila Times

Mar 24, 2025
pulisher
Mar 24, 2025

BridgeBio Pharma to Present Cardiovascular Outcomes Data from ATTRibute-CM Study at ACC Annual Scientific Sessions 2025 - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Achondroplasia Treatment Market Size in 7MM is expected to grow - openPR

Mar 24, 2025
pulisher
Mar 23, 2025

Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - MSN

Mar 23, 2025
pulisher
Mar 22, 2025

BridgeBio Pharma Inc (BBIO) Announces Equity Grants to New Employees - GuruFocus.com

Mar 22, 2025
pulisher
Mar 21, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 21, 2025
pulisher
Mar 21, 2025

Bridgebio Pharma reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:05 pm EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam Drug Approval Brings Cardiomyopathy Competition to Pfizer, BridgeBio Pharma - MedCity News

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam prices heart drug at premium to rivals - BioPharma Dive

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

NYSE Content advisory: Pre-Market update + Stocks try for weekly gains - The Globe and Mail

Mar 21, 2025
pulisher
Mar 21, 2025

BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion’s board - Endpoints News

Mar 21, 2025
pulisher
Mar 20, 2025

Alnylam Joins Competitive ATTR-CM Market With Amvuttra Approval - News & Insights

Mar 20, 2025
pulisher
Mar 20, 2025

Achondroplasia Market on Track for Major Expansion by 2034, - openPR

Mar 20, 2025
pulisher
Mar 19, 2025

UBS Adjusts Price Target on BridgeBio Pharma to $65 From $62, Maintains Buy Rating - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Trend Tracker for (BBIO) - Stock Traders Daily

Mar 19, 2025
pulisher
Mar 18, 2025

BridgeBio Announces CFO Succession - The Manila Times

Mar 18, 2025
pulisher
Mar 17, 2025

BridgeBio Pharma Appoints New President and CFO - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

BridgeBio Pharma announces CFO succession -March 17, 2025 at 04:30 pm EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

BridgeBio Pharma Names New CFO -March 17, 2025 at 04:21 pm EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

BridgeBio Promotes Internal Leader to CFO Role, Ensuring Strategic Continuity - StockTitan

Mar 17, 2025
pulisher
Mar 13, 2025

Lobbying Update: $30,000 of BRIDGEBIO PHARMA INC. lobbying was just disclosed - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

BridgeBio Pharma’s SWOT analysis: innovative pipeline drives stock potential - Investing.com

Mar 13, 2025
pulisher
Mar 10, 2025

BridgeBio Pharma director Hannah Valantine sells $419,499 in stock By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

BridgeBio Pharma director Hannah Valantine sells $419,499 in stock - Investing.com

Mar 10, 2025
pulisher
Mar 09, 2025

Genetic Disorder L.P. Kkr Sells 6,000,000 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Kkr sells $197.76 million in BridgeBio Pharma stock By Investing.com - Investing.com Australia

Mar 08, 2025
pulisher
Mar 08, 2025

(BBIO) On The My Stocks Page - Stock Traders Daily

Mar 08, 2025

Bridgebio Pharma Inc (BBIO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
자본화:     |  볼륨(24시간):